Literature DB >> 30657681

Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.

Florian Reichart1, Oleg V Maltsev1, Tobias G Kapp1, Andreas F B Räder1, Michael Weinmüller1, Udaya Kiran Marelli2, Johannes Notni3, Alexander Wurzer3, Roswitha Beck3, Hans-Jürgen Wester3, Katja Steiger4, Salvatore Di Maro5, Francesco Saverio Di Leva6, Luciana Marinelli6, Markus Nieberler7, Ute Reuning, Markus Schwaiger, Horst Kessler1.   

Abstract

Integrins play important roles in physiological and pathophysiological processes. Among the RGD-recognizing integrin subtypes, the αvβ8 receptor is emerging as an attractive target because of its involvement in various illnesses, such as autoimmune diseases, viral infections, and cancer. However, its functions have, so far, not been investigated in living subjects mainly because of the lack of a selective αvβ8 ligand. Here, we report the design and potential medical applications of a cyclic octapeptide as the first highly selective small-molecule ligand for αvβ8. Remarkably, this compound displays low nanomolar αvβ8 binding affinity and a strong discriminating power of at least 2 orders of magnitude versus other RGD-recognizing integrins. Peptide functionalization with fluorescent or radioactive labels enables the selective imaging of αvβ8-positive cells and tissues. This new probe will pave the way for detailed characterization of the distinct (patho)physiological role of this relatively unexplored integrin, providing a basis to fully exploit the potential of αvβ8 as a target for molecular diagnostics and personalized therapy regimens.

Entities:  

Year:  2019        PMID: 30657681     DOI: 10.1021/acs.jmedchem.8b01588

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Identification of adeno-associated virus variants for gene transfer into human neural cell types by parallel capsid screening.

Authors:  Lea Jessica Flitsch; Kathleen Börner; Christian Stüllein; Simon Ziegler; Vera Sonntag-Buck; Ellen Wiedtke; Vesselina Semkova; Si Wah Christina Au Yeung; Julia Schlee; Mohamad Hajo; Mona Mathews; Beatrice Stefanie Ludwig; Susanne Kossatz; Horst Kessler; Dirk Grimm; Oliver Brüstle
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

2.  Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites.

Authors:  Paris R Watson; Timothy W Craven; Xinting Li; Stephen Rettie; Parisa Hosseinzadeh; Fátima Pardo-Avila; Asim K Bera; Vikram Khipple Mulligan; Peilong Lu; Alexander S Ford; Brian D Weitzner; Lance J Stewart; Adam P Moyer; Maddalena Di Piazza; Joshua G Whalen; Per Jr Greisen; David W Christianson; David Baker
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

3.  Molecular Signature of Astrocytes for Gene Delivery by the Synthetic Adeno-Associated Viral Vector rAAV9P1.

Authors:  Amelie Bauer; Matteo Puglisi; Dennis Nagl; Joel A Schick; Thomas Werner; Andreas Klingl; Jihad El Andari; Veit Hornung; Horst Kessler; Magdalena Götz; Dirk Grimm; Ruth Brack-Werner
Journal:  Adv Sci (Weinh)       Date:  2022-04-10       Impact factor: 17.521

Review 4.  It's Time to Shift the Paradigm: Translation and Clinical Application of Non-αvβ3 Integrin Targeting Radiopharmaceuticals.

Authors:  Susanne Kossatz; Ambros Johannes Beer; Johannes Notni
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

Review 5.  Emerging therapeutic opportunities for integrin inhibitors.

Authors:  R J Slack; S J F Macdonald; J A Roper; R G Jenkins; R J D Hatley
Journal:  Nat Rev Drug Discov       Date:  2021-09-17       Impact factor: 84.694

6.  αVβ8 integrin targeting to prevent posterior capsular opacification.

Authors:  Mahbubul H Shihan; Samuel G Novo; Yan Wang; Dean Sheppard; Amha Atakilit; Thomas D Arnold; Nicole M Rossi; Adam P Faranda; Melinda K Duncan
Journal:  JCI Insight       Date:  2021-11-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.